Search clinical trials for: CNTO 1959

Total 1197 results

Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Centocor, Inc.

Completed

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis

Palmoplantaris Pustulosis

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

Arthritis, Psoriatic

Israel, United States, Germany, Taiwan, Korea, Republic of, Malaysia, China, Georgia, Hungary, Poland, Spain, Philippines, Italy, Canada, Bulgaria, Russian Federation, Serbia, Slovenia, Bosnia and Herzegovina, Greece, Ukraine, Cze... and more
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) (Discover-1)

Arthritis, Psoriatic

United States, Canada, Taiwan, Hungary, Malaysia, Germany, Czechia, Korea, Republic of, Russian Federation, Spain, Australia, Ukraine, Poland
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States, Canada, Poland
Janssen Pharmaceutical K.K.

Completed

Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus

Healthy | Diabetes Mellitus, Type 2

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab in Participants With Active Lupus Nephritis (ORCHID-LN)

Lupus Nephritis

United States, Taiwan, Mexico, Spain, Russian Federation, Thailand, Poland, Argentina, Ukraine
Janssen Research & Development, LLC

Completed

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Arthritis, Rheumatoid

Poland, Ukraine, Colombia, Bulgaria, United States, Singapore, Russian Federation, Argentina, Hungary, Chile, Czech Republic
Janssen Research & Development, LLC

Completed

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

Healthy

United States
Janssen-Cilag International NV

Completed

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Healthy

Belgium
Centocor, Inc.

Completed

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

United States, Australia, Taiwan, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Poland, Hungary
Washington University School of Medicine

Completed

Exome Sequencing for Atypical Femoral Fractures

Osteoporosis | Atypical Femoral Fractures | Bisphosphonate Therapy
Centocor, Inc.

Terminated

A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Janssen Pharmaceutical K.K.

Withdrawn

Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy | Visual Acuity

Japan
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Poland, Germany, Taiwan, Malaysia, Korea, Republic of, Czech Republic, Russian Federation, Hungary
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (VOYAGE 2)

Psoriasis

United States, Australia, Poland, Germany, Spain, Korea, Republic of, Canada, Russian Federation, Czechia
T3D Therapeutics, Inc.
National Institute on Aging (NIA); Alzheimer's Association; Clinilabs, Inc.

Completed

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Alzheimer Disease

United States
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Vyome Therapeutics Inc.

Unknown

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

Acne Vulgaris

United States
Centocor, Inc.

Completed

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

Asthma

Germany, United Kingdom, Belgium
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Janssen Research & Development, LLC

Completed

A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16

Healthy Volunteers and Asthma

United Kingdom, Canada, Netherlands, Germany, Denmark, Belgium
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Healthy | Systemic Lupus Erythematosus

United States, Spain, Romania, Taiwan, Belgium, Poland, Moldova, Republic of
Centocor, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Pulmonary Fibrosis

United States, Canada, Netherlands, Belgium, Germany
Rakuten Medical, Inc.
National Cancer Institute (NCI); Shimadzu Corporation

Recruiting

ASP-1929 Photoimmunotherapy (PIT) Study in in Patients With Recurrent Head/Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck

United States
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects

Allergy

United States
Centocor, Inc.

Completed

First Study of the Safety of CNTO 888 in Patients With Solid Tumors

Cancer
Centocor, Inc.

Completed

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

Healthy
GlycoMimetics Incorporated

Terminated

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Breast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast Cancer

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Advanced Malignant Cancer

China
Regeneron Pharmaceuticals

Completed

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Allergy

United Kingdom, New Zealand, Netherlands, Sweden
Regeneron Pharmaceuticals

Completed

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Cat Allergy | Mild Asthma

France
GlycoMimetics Incorporated
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration

United States
Disc Medicine, Inc

Enrolling by invitation

Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP

Erythropoietic Protoporphyria

United States, Australia
Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States

3

Subscribe